HIGHFDA DRUG

Cipla Lanreotide Acetate Injection Recall: 15,221 Syringes Over Particulate Matter (2026)

Cipla USA, Inc. is recalling 15,221 Lanreotide Acetate Injection syringes nationwide in the United States after detecting particulate matter. The defect is the presence of particulate matter in the injectable solution. Healthcare providers and patients should stop using the product immediately and contact Cipla USA for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
January 2, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
January 2, 2026
Hazard Level
HIGH
Brands
LANREOTIDE ACETATE, Cipla USA Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
LANREOTIDE ACETATE, Cipla USA Inc.
Product type
Lanreotide Acetate Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe
Model numbers
4301954IR1, 4301994IR1, 4301995IR1, 4301996IR1, 4400005IR1, 4400006IR1, 4400007IR1, 4400124IR1 +2 more
UPC codes
69097-870, 69097-880, 69097-890, 69097-880-67, 69097-890-67, 69097-870-67
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    January 2, 2026

  2. Reported by FDA DRUG

    January 21, 2026

  3. RecallRadar source check

    March 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Presence of Particulate Matter.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance

About This Product

Lanreotide Acetate Injection is a prescription medication delivered by subcutaneous injection. It is used to manage certain neuroendocrine conditions and tumors. The recall covers multiple lots distributed nationwide in the United States.

Why This Is Dangerous

Particulate matter in an injectable solution can cause local or systemic reactions and may pose health risks depending on the nature of the particulates and injection site.

Industry Context

This recall is not described as part of a broader industry pattern in the notice.

Real-World Impact

Patients on Lanreotide injections may experience delays in treatment and must transition to alternative therapy as guided by a clinician. The recall creates a potential risk if particulates are injected.

Practical Guidance

How to identify if yours is affected

  1. Verify NDC 69097-870-67 on the vial label.
  2. Note expiry dates associated with each lot (e.g., 31/10/2026 or 30/11/2026).

Where to find product info

Recall details are on the FDA enforcement page linked in the notice and on Cipla USA communications.

What timeline to expect

Replacement or guidance timeline is not specified in the notice. Check with Cipla USA or FDA for updates.

If the manufacturer is unresponsive

  • Escalate to FDA MedWatch if you experience adverse effects.
  • Contact your healthcare provider for alternatives and document all communications.

How to prevent similar issues

  • Regularly check recall notices for prescription medications you use.
  • Verify lot numbers and expiry dates before administration.
  • Maintain a current list of medications and their lot numbers for quick reference in recalls.

Documentation advice

Keep the recall notice, packaging, lot numbers, and any correspondence with the manufacturer or healthcare provider. Document adverse events with dates and symptoms.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Lanreotide Acetate Injection, 120 mg/0.5 mL. 0.5 mL per pre-filled syringe. For deep subcutaneous injection. NDC 69097-870-67. Sold nationwide in the USA. Manufactured for Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. Quantity: 15,221 syringes. Recall Date: 2026-01-02. Status: ACTIVE. Distribution: Nationwide in the USA.

Key Facts

  • Manufacturer: Cipla USA, Inc.

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeLanreotide Acetate Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe
Sold At
Multiple Retailers

Product Details

Model Numbers
4301954IR1
4301994IR1
4301995IR1
4301996IR1
4400005IR1
+5 more
UPC Codes
69097-870
69097-880
69097-890
+3 more
Affected States
ALL
Report Date
January 21, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Cipla USA Recalls Lanthanum Carbonate Tablets Over Stability Issues

Cipla USA recalled 1,180 boxes of Lanthanum Carbonate chewable tablets on October 24, 2025. The recall follows a failure to meet stability specifications for hardness tests. Consumers and healthcare providers must stop using the product immediately.

LANTHANUM CARBONATE
Failed stability
Read more